Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Research sheds light on the mystery cause of idiopathic pulmonary fibrosis

Research sheds light on the mystery cause of idiopathic pulmonary fibrosis

Researchers develop multi-channel recording device for lung sound analysis

Researchers develop multi-channel recording device for lung sound analysis

Researchers develop telomerase gene therapy for treating different pathologies

Researchers develop telomerase gene therapy for treating different pathologies

New therapy for flu may prove effective against many other pathogenic virus infections

New therapy for flu may prove effective against many other pathogenic virus infections

New therapy developed for flu infections may also prove effective against HIV, COVID-19

New therapy developed for flu infections may also prove effective against HIV, COVID-19

Scientists are developing new treatment option for lung fibrosis

Scientists are developing new treatment option for lung fibrosis

Researchers identify a genetic basis for ANCA-associated vasculitis

Researchers identify a genetic basis for ANCA-associated vasculitis

Researchers identify genetic basis for anti-neutrophil cytoplasmic antibody-associated vasculitis

Researchers identify genetic basis for anti-neutrophil cytoplasmic antibody-associated vasculitis

Researchers assess molecular basis of SARS-CoV-2 severity and poor outcomes in lung disease

Researchers assess molecular basis of SARS-CoV-2 severity and poor outcomes in lung disease

Blood purification outside the body in COVID-19 patients

Blood purification outside the body in COVID-19 patients

TL1A and its receptor could reduce fibrosis and tissue remodeling in patients with severe lung disease

TL1A and its receptor could reduce fibrosis and tissue remodeling in patients with severe lung disease

Study may help develop treatment for age-related pulmonary fibrosis

Study may help develop treatment for age-related pulmonary fibrosis

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

IRB Barcelona team receives ERC grant to develop new drugs against fibrosis

IRB Barcelona team receives ERC grant to develop new drugs against fibrosis

Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery

Groundbreaking study identifies unique lung cells that may drive pulmonary fibrosis

Groundbreaking study identifies unique lung cells that may drive pulmonary fibrosis

Gene expression networks flag potential therapeutic targets for SARS-CoV-2

Gene expression networks flag potential therapeutic targets for SARS-CoV-2

Air pollution may lead to interstitial lung diseases

Air pollution may lead to interstitial lung diseases

Molecular approach can improve diagnosis of pulmonary hypertension

Molecular approach can improve diagnosis of pulmonary hypertension

Smoking increases ACE2 protein in the lungs which may promote COVID-19 infection

Smoking increases ACE2 protein in the lungs which may promote COVID-19 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.